Human mscs promotes colorectal cancer epithelial–mesenchymal transition and progression via ccl5/β-catenin/slug pathway

Cell Death and Disease

Volumn 8, Issue 5, 2017, Pages

  Chen, Ke ^a   Liu, Qianqian ^a   Tsang, Lai Ling ^b   Ye, Qiao ^a   Chan, Hsiao Chang ^b   Sun, Yunwei ^a   Jiang, Xiaohua ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CCL5 PROTEIN, HUMAN; CCR1 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR1; RANTES; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR;

ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; COLORECTAL TUMOR; DISEASE EXACERBATION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL5; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MESENCHYMAL STROMAL CELLS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PHENOTYPE; RECEPTORS, CCR1; SIGNAL TRANSDUCTION; SNAIL FAMILY TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85032896986     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.138     Document Type: Article

References (51)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104–117.
2. Yokota T, Kunii Y, Kagami M, Yamada Y, Takahashi M, Kikuchi S et al. Metastatic breast carcinoma masquerading as primary colon cancer. Am J Gastroenterol 2000; 95: 3014–3016.
3. Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 2013; 14: 589.
4. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007; 101: 816–829.
5. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904–5912.
6. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392–401.
7. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331–4339.
8. Mishra PJ, Merlino G. A traitor in our midst: mesenchymal stem cells contribute to tumor progression and metastasis. Future Oncol 2008; 4: 745–749.
9. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257–272.
10. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96: 1593–1603.
11. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012; 11: 812–824.
12. Tang RJ, Shen SN, Zhao XY, Nie YZ, Xu YJ, Ren J et al. Mesenchymal stem cells-regulated Treg cells suppress colitis-associated colorectal cancer. Stem Cell Res Ther 2015; 6: 71.
13. Nasuno M, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nakagaki S et al. Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Stem Cells 2014; 32: 913–925.
14. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011; 141: 1046–1056.
15. De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013; 62: 550–560.
16. Mele V, Muraro MG, Calabrese D, Pfaff D, Amatruda N, Amicarella F et al. Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-beta. Int J Cancer 2014; 134: 2583–2594.
17. Wu XB, Liu Y, Wang GH, Xu X, Cai Y, Wang HY et al. Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-kappaB activation. Sci Rep 2016; 6: 21420.
18. Lin SJ, Chang KP, Hsu CW, Chi LM, Chien KY, Liang Y et al. Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma. J Proteomics 2013; 94: 186–201.
19. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175–184.
20. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267: 271–285.
21. Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999; 79: 1025–1031.
22. Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S et al. Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 2008; 97: 445–450.
23. Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators inflamm 2014; 2014: 292376.
24. Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE 2011; 6: e28842.
25. Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ et al. Chemokine (C-C Motif) ligand 5 is involved in tumor-associated dendritic cell-mediated colon cancer progression through non-coding RNA MALAT-1. J Cell Physiol 2015; 230: 1883–1894.
26. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M et al. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008; 123: 2031–2040.
27. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012; 72: 1092–1102.
28. Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y et al. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013; 23: 394–408.
29. Kauts ML, Pihelgas S, Orro K, Neuman T, Piirsoo A. CCL5/CCR1 axis regulates multipotency of human adipose tissue derived stromal cells. Stem Cell Res 2013; 10: 166–178.
30. Lu L, Zhang X, Zhang M, Zhang H, Liao L, Yang T et al. RANTES and SDF-1 are keys in cell-based therapy of TMJ osteoarthritis. J Dent Res 2015; 94: 1601–1609.
31. Wise AF, Williams TM, Kiewiet MB, Payne NL, Siatskas C, Samuel CS et al. Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury. Am J Physiol Renal Physiol 2014; 306: F1222–F1235.
32. Findlay VJ, Wang C, Watson DK, Camp ER. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 2014; 21: 181–187.
33. Sakai D, Tanaka Y, Endo Y, Osumi N, Okamoto H, Wakamatsu Y. Regulation of Slug transcription in embryonic ectoderm by beta-catenin-Lef/Tcf and BMP-Smad signaling. Dev Growth Differ 2005; 47: 471–482.
34. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883–899.
35. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20: 65–71.
36. Aran D, Lasry A, Zinger A, Biton M, Pikarsky E, Hellman A et al. Widespread parainflammation in human cancer. Genome Biol 2016; 17: 145.
37. Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol 2016; 17: 230–240.
38. Bates RC, Mercurio AM. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 2005; 4: 365–370.
39. Bates RC, Pursell BM, Mercurio AM. Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs 2007; 185: 29–39.
40. Gout S, Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron. 2008; 1: 69–83.
41. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002; 8: 3803–3812.
42. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557–563.
43. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030–1041.
44. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007; 101: 135–146.
45. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415–428.
46. Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z, You T. HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett 2014; 355: 130–140.
47. Yao C, Su L, Shan J, Zhu C, Liu L, Liu C et al. IGF/STAT3/NANOG/Slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells 2016; 34: 820–831.
48. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192–1205.
49. Liu Y, Jiang X, Zhang X, Chen R, Sun T, Fok KL et al. Dedifferentiation-reprogrammed mesenchymal stem cells with improved therapeutic potential. Stem Cells 2011; 29:2077–2089.
50. Shang YC, Wang SH, Xiong F, Zhao CP, Peng FN, Feng SW et al. Wnt3a signaling promotes proliferation, myogenic differentiation, and migration of rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin 2007; 28: 1761–1774.
51. Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp 2011: 51.